Trouble Falling Asleep: the Sleep Onset Insomnia Pattern
For the night that ends well and holds well — but cannot begin.
If the assessment placed you here, the difficulty is the start of the night. The light is off, the body is willing, but sleep refuses to arrive — sometimes for an hour, sometimes for two or three. Once you do finally sleep, the rest of the night is largely intact. It is the wait that is the problem.
What is actually happening in sleep onset insomnia
A successful sleep onset depends on three signals lining up: the brain's wakefulness drive stepping back, the body's core temperature dropping, and the body's natural melatonin onset arriving on time. Sleep onset insomnia is what happens when one or more of those signals are mistimed — most often because endogenous melatonin is reduced or delayed, the wake-drive lingers too long, or the thermoregulatory dip is muted.
The clinical job here is narrow: bring sleep on at the right time, without a morning hangover. Every agent that works for this pattern acts in the same window — so a single well-formulated combined dose tends to outperform a staggered protocol.
The Slumbr approach
For the sleep-onset pattern the strongest evidence sits with CBT-I and, where clinically appropriate, prescription options, and both start with a free specialist consultation. Non-prescription support for this pattern is deliberately limited: Slumbr Glycine bedtime powder, taken 30 to 45 minutes before bed, supports the drop in core temperature that helps sleep begin.
A note on melatonin dosing: more is not better. Where melatonin is prescribed for sleep onset, we use 1 mg immediate-release, because that is the physiological dose where the evidence sits. The 3–10 mg preparations widely sold elsewhere saturate receptors and can blunt your natural timing rather than support it. In South Africa melatonin is a Schedule 4 medicine, so it is prescribed after a consultation rather than sold from this page.
A note on how melatonin is used at Slumbr
The same molecule is prescribed for three different purposes — and the timing is different, because the purpose is different.
- For falling asleep (immediate-release, 1 mg): taken 30–45 minutes before bed, as a sleep-onset signal.
- For sleep that ends too early (prolonged-release): taken at bedtime, to extend melatonergic support across the back half of the night.
- For a body clock running at the wrong time (immediate-release, timed): taken hours before your target bedtime, as a clock-shifting signal — not as a sleep aid.
Same drug, three different uses. Timing is the variable, and it matters.
When prescription is the right next step
If sleep-onset difficulty has lasted more than three months, or is producing significant daytime impact, a specialist consultation discusses prescription options. The mechanism-aligned first-line is the dual orexin receptor antagonist class — direct quietening of the brain's wakefulness signal, no dependence, low next-day impairment. For older adults, or for those whose onset difficulty overlaps with some mid-night wakefulness, prolonged-release melatonin is a separate option. Short-course agents have their place in acute crises but are deliberately time-limited — never a daily medication.
How telephonic consultations work
Within the wider plan
For chronic insomnia, Cognitive Behavioural Therapy for Insomnia (CBT-I) is the leading evidence-based approach. Where it fits your situation, the Slumbr consultation can discuss or signpost CBT-I — it pairs particularly well with either non-prescription support or a prescription. Both the American Academy of Sleep Medicine's 2021 clinical practice guideline and the European Insomnia Guideline 2023 recommend CBT-I as the first-line treatment for chronic insomnia.